CVKD
Cadrenal Therapeutics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$15.98M
P/E Ratio
—
EPS
$-5.59
Beta
1.83
52W High
$15.99
52W Low
$4.21
50-Day MA
$5.56
200-Day MA
$9.20
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies for renal diseases and kidney-related disorders. Utilizing its proprietary drug platforms, the company is committed to addressing significant unmet medical needs through a robust pipeline of drug candidates currently in advanced clinical trials. With a strong emphasis on scientific innovation and patient-centric solutions, Cadrenal is poised to deliver transformative treatments that could significantly enhance renal health outcomes, underscoring its potential for substantial growth in the evolving biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.05M |
| Operating Margin | 0.00% |
| Return on Equity | -300.60% |
| Return on Assets | -139.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.72 |
| Price-to-Book | 8.77 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.08M |
| Float | $2.38M |
| % Insiders | 18.23% |
| % Institutions | 5.97% |
Historical Volatility
HV 10-Day
70.62%
HV 20-Day
94.13%
HV 30-Day
87.17%
HV 60-Day
94.31%
HV Rank
46.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($27.67 target)
2
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026